Cover Image
市場調查報告書

Stemline Therapeutics, Inc.- 產品平台檢討

Stemline Therapeutics, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 204928
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
Stemline Therapeutics, Inc.- 產品平台檢討 Stemline Therapeutics, Inc. - Product Pipeline Review - 2016
出版日期: 2016年08月24日 內容資訊: 英文 49 Pages
簡介

Stemline Therapeutics, Inc. 是開發臨床階段所使用的醫藥品的生物製藥公司,正在開發以癌症幹細胞與巨大腫瘤為標的的Oncology compound。

本報告提供Stemline Therapeutics, Inc.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Stemline Therapeutics, Inc.的基本資料

Stemline Therapeutics, Inc.概要

  • 主要資訊
  • 企業資料

Stemline Therapeutics, Inc.:R&D概要

  • 主要的治療範圍

Stemline Therapeutics, Inc.:開發平台(管線)的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Stemline Therapeutics, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Stemline Therapeutics, Inc.:藥物簡介

  • SL-401
  • SL-701
  • Monoclonal Antibody Targeting CD133 For Cancer
  • Monoclonal Antibody Targeting Frizzled Receptor For Cancer
  • Monoclonal Antibody Targeting Glypican-3 For Cancer
  • Monoclonal Antibody Targeting Patched For Cancer
  • Monoclonal Antibody Targeting Smoothened For Cancer
  • Monoclonal Antibody Targeting Tie-1 Receptor For Cancer
  • SL-101
  • SL-201
  • SL-202
  • SL-301
  • SL-302
  • SL-501
  • SL-601

Stemline Therapeutics, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Stemline Therapeutics, Inc.:最近的開發平台趨勢

Stemline Therapeutics, Inc.:暫停中的計劃

Stemline Therapeutics, Inc.:總公司和子公司的所地

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08133CDB

Summary

Global Markets Direct's, 'Stemline Therapeutics, Inc. - Product Pipeline Review - 2016', provides an overview of the Stemline Therapeutics, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Stemline Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Stemline Therapeutics, Inc.
  • The report provides overview of Stemline Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Stemline Therapeutics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Stemline Therapeutics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Stemline Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Stemline Therapeutics, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Stemline Therapeutics, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Stemline Therapeutics, Inc. Snapshot
    • Stemline Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Stemline Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Stemline Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Stemline Therapeutics, Inc. - Pipeline Products Glance
    • Stemline Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Stemline Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Stemline Therapeutics, Inc. - Drug Profiles
    • SL-401
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SL-701
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SL-801
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit IL-3RA for Autoimmune Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize Frizzled Receptor for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize Patched for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize Tie-1 Receptor for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CD133 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Glypican-3 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Smoothened for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SL-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SL-201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SL-202
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SL-301
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SL-302
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SL-501
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SL-601
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Stemline Therapeutics, Inc. - Pipeline Analysis
    • Stemline Therapeutics, Inc. - Pipeline Products by Target
    • Stemline Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Stemline Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Stemline Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Stemline Therapeutics, Inc. - Recent Pipeline Updates
  • Stemline Therapeutics, Inc. - Dormant Projects
  • Stemline Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Stemline Therapeutics, Inc., Key Information
  • Stemline Therapeutics, Inc., Key Facts
  • Stemline Therapeutics, Inc. - Pipeline by Indication, 2016
  • Stemline Therapeutics, Inc. - Pipeline by Stage of Development, 2016
  • Stemline Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • Stemline Therapeutics, Inc. - Phase II, 2016
  • Stemline Therapeutics, Inc. - Phase I, 2016
  • Stemline Therapeutics, Inc. - Preclinical, 2016
  • Stemline Therapeutics, Inc. - Pipeline by Target, 2016
  • Stemline Therapeutics, Inc. - Pipeline by Route of Administration, 2016
  • Stemline Therapeutics, Inc. - Pipeline by Molecule Type, 2016
  • Stemline Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Stemline Therapeutics, Inc. - Recent Pipeline Updates, 2016
  • Stemline Therapeutics, Inc. - Dormant Developmental Projects,2016

List of Figures

  • Stemline Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016
  • Stemline Therapeutics, Inc. - Pipeline by Stage of Development, 2016
  • Stemline Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • Stemline Therapeutics, Inc. - Pipeline by Top 10 Target, 2016
  • Stemline Therapeutics, Inc. - Pipeline by Route of Administration, 2016
  • Stemline Therapeutics, Inc. - Pipeline by Molecule Type, 2016
  • Stemline Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top